For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older.

Not an actual HS patient



HUMIRA targets and blocks TNF-α to help address HS inflammation beneath the skin.1-3

The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown.

The only FDA-approved treatment for hidradenitis suppurativa.
Female HS patient standing and smiling.

Only HUMIRA is FDA-approved to provide significant results in moderate to severe HS patients at Week 12

See data in PIONEER I and II trials:

Primary endpoint*

*Many adults with moderate to severe HS achieved HiSCR at Week 12, defined as ≥50% reduction from baseline in abscess and inflammatory nodule count, with no increase in abscess and draining tunnel counts.4

Are you prescribing HUMIRA to patients in your practice?


View HUMIRA efficacy in HS

View post hoc analysis of lesion spread in HUMIRA-treated patients


View HUMIRA efficacy in HS

Learn more about how HUMIRA works

I am not a prescriber of medicine

View and download helpful HUMIRA resources

Learn about access for your HUMIRA patients

Female HS patient standing and smiling.
Every other week 80 mg maintenance dose for appropriate patients.

Half the injections with 80 mg every-other-week (EOW) maintenance dosing

in appropriate patients (≥12 years, ≥132 lbs) after 2 initiation doses compared to 40 mg weekly maintenance dosing.1

Video thumbnail of navigating the unknown

"Navigating the Unknown"

Hear real stories of HS from frontline physicians and actual patients. They are stories of systemic inflammation, lesions, and scarring.

Male HS patient with arms crossed and smiling.


1% non-preferred

99% of National Commercial patients have access to HUMIRA as a preferred, first-line targeted immunomodulator (TIM) on formulary.5


National Commercial Formulary coverage under the pharmacy benefit as of May 2022

Disadvantaged means a restriction (eg, prior authorization, step edit, quantity limits, or other medical policies) to a product that is not applied consistently across the entire therapeutic class.

Formulary Definitions: Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit or are placed on a higher tier. First-line refers to a preferred or parity formulary status.

Male HS patient with arms crossed and smiling.
HUMIRA Complete Savings Card
HUMIRA Complete Logo

In addition to forms and resources for your practice, HUMIRA Complete provides support and tools to help patients start and stay on track with their treatment—including injection training, the HUMIRA Complete App, and more.